This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Roth BJ , Dreicer R , Einhorn LH , Neuberg D , Johnson DH , Smith JL , Hudes GR , Schultz SM , Loehrer PJ
Significant Activity of Paclitaxel in Advanced Transitional- Cell Carcinoma of the Urothelium - a Phase-Ii Trial of the Eastern-Cooperative-Oncology-Group
Journal of Clinical Oncology. 1994 Nov;12(11) :2264-2270
AbstractPurpose: To assess the efficacy and toxicity of single-agent paclitaxel as first-line chemotherapy in patients with locally advanced or mel astatic transitional-cell carcinoma of the urothelium. Patients end Methods: Twenty-six eligible patients were enrolled onto this cooperative group study and treated with paclitaxel at a dosage of 250 mg/m(2) by 24-hour continuous infusion every 21 days until progression or patient intolerance. All patients received recombinant human granulocyte colony-stimulating factor (rhG-CSF) at 5 mu g/kg/d for at least 10 days during each cycle. Results: Eleven of 26 patients (42%; 95% confidence interval [CI], 23% to 63%) demonstrated an objective response, with seven achieving a complete clinical response (CR) (27%; 95% CI, 12% to 48%) and four (15%) a partial response (PR). The median duration of response in the 11 responders is 7+ months (range, 4 to 17), with five responders (four CRs, one PR) remaining progression- free at 5, 6, 10, 12, and 16 months from the start of therapy. The estimated median survival duration for all patients is 8.4 months. Hematologic toxicity consisted of anemia (12% grade 3) and granulocytopenia (4% grade 3, 19% grade 4), with two patients developing granulocytopenic fevers. Nonhematologic toxicity included grade 3 mucositis in 11%, grade 3 neuropathy in 11%, and grade 4 diarrhea in 4%. Conclusion: Single-agent paclitaxel at this dosage and schedule is one of the most active single agents in previously untreated patients with advanced urothelial carcinoma, and is well tolerated by this patient population when given with hematopoetic growth factor support. (C) 1994 by American Society of Clinical Oncology.
NotesEnglish Article PP880 J CLIN ONCOL